Skip to main content

Table 2 Changes in Medication Costs for Subgroupsa

From: Medication costs during an 18 month clinical trial of obesity treatment among patients encountered in primary care

  Month 0 Month 6 Month 18 Change: Month 0 to Month 6; p value Change: Month 6 to Month 18; p value Change: Month 0 to Month 18; p value
Diabetes (DM) 281.56 298.01 250.66 16.45 −47.36 −30.9
or Hypertension (59.89) (66.34) (56.42) (95.95); (97.21); (91.27);
(HTN) (n = 59)     0.57 0.31 0.37
10 % weight 232.78 215.38 213.48 −17.4 −1.9 −19.3
lossa, b (102.17) (92.43) (94.8) (150.74); (148.22); (160.1);
(n = 21)     0.45 0.49 0.45
DM or HTN and 256.05 235.86 233.43 −20.2 −2.43 −22.63
10 % weight (102.85) (93.18) (96.77) (151.39); (152.07); (161.71);
lossa, b (n = 19)     0.45 0.49 0.44
  1. a Data are presented as mean (se) in 2013 U.S. dollar amounts
  2. a, b Participants who lost at least 10 % of starting weight from month 0 to month 6